Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. RDNT
RDNT logo

RDNT Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy RadNet Inc (RDNT) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Buy
Latest Price
53.740
1 Day change
1.74%
52 Week Range
85.840
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

RadNet Inc (RDNT) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The stock has shown positive price momentum, hedge funds are increasing their positions significantly, and analysts maintain favorable ratings with high price targets. Despite the lack of recent news or congress trading data, the technical indicators and options data suggest a balanced sentiment, and the stock's potential for long-term growth in the imaging and radiotherapeutics sectors makes it an attractive investment.

Technical Analysis

The MACD histogram is positive (0.0235), indicating bullish momentum, though it is contracting. RSI is neutral at 39.19, suggesting no overbought or oversold conditions. Moving averages are converging, showing no strong directional trend. Key support is at 52.03, and resistance is at 59.028, with the stock currently trading near its pivot level of 55.529.

Options Data

Bullish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
9
Buy
2

Positive Catalysts

  • Hedge funds are significantly increasing their positions (+139.49% last quarter). Analysts maintain Buy and Overweight ratings with price targets of $65 and $83, indicating strong confidence in the stock's growth potential. The stock has shown positive price momentum with a 1.74% regular market gain and 2.01% post-market gain.

Neutral/Negative Catalysts

  • No significant insider trading trends. RSI and MACD do not provide strong buy signals. Lack of recent news or congress trading data.

Financial Performance

No financial data available for the latest quarter.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Barclays and B. Riley have lowered price targets but maintain positive ratings (Overweight and Buy), citing strong growth in imaging and PET volume.

Wall Street analysts forecast RDNT stock price to rise
6 Analyst Rating
Wall Street analysts forecast RDNT stock price to rise
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 52.820
sliders
Low
86
Averages
90.17
High
95
Current: 52.820
sliders
Low
86
Averages
90.17
High
95
Barclays
Andrew Mok
Overweight
to
Buy
downgrade
$70 -> $65
AI Analysis
2026-05-20
Reason
Barclays
Andrew Mok
Price Target
$70 -> $65
AI Analysis
2026-05-20
downgrade
Overweight
to
Buy
Reason
Barclays analyst Andrew Mok lowered the firm's price target on RadNet to $65 from $70 and keeps an Overweight rating on the shares. The firm says RadNet is outperforming Lumexa on advanced volume growth and imaging segment pricing.
B. Riley
Buy
downgrade
$87 -> $83
2026-05-01
Reason
B. Riley
Price Target
$87 -> $83
2026-05-01
downgrade
Buy
Reason
B. Riley lowered the firm's price target on RadNet to $83 from $87 and keeps a Buy rating on the shares. The Q1 reports across the radiotherapeutics and imaging agents point to a multi-indication PET volume growth, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for RDNT
Unlock Now

People Also Watch